4-arylcyclohexylalanine analogs as potent, selective, and orally active inhibitors of dipeptidyl peptidase IV.

A novel series of 4-arylcyclohexylalanine DPP-4 inhibitors was synthesized and tested for inhibitory activity as well as selectivity over the related proline-specific enzymes DPP-8 and DPP-9. Optimization of this series led to 28 (DPP-4 IC(50)=4.8 nM), which showed an excellent pharmacokinetic profile across several preclinical species. Evaluation of 28 in an oral glucose tolerance test demonstrated that this compound effectively reduced glucose excursion in lean mice.

[1]  A. Woods,et al.  Dipeptidyl peptidase IV inhibition for the treatment of type 2 diabetes: potential importance of selectivity over dipeptidyl peptidases 8 and 9. , 2005, Diabetes.

[2]  Dipeptidyl peptidase IV inhibitors for the treatment of diabetes. , 2004, Journal of medicinal chemistry.

[3]  Aleksandr Petrov,et al.  4-Amino cyclohexylglycine analogues as potent dipeptidyl peptidase IV inhibitors. , 2004, Bioorganic & medicinal chemistry letters.

[4]  Koen Augustyns,et al.  Inhibitors of proline-specific dipeptidyl peptidases: DPP IV inhibitors as a novel approach for the treatment of Type 2 diabetes , 2005 .

[5]  P. Van der Veken,et al.  Dipeptidyl peptidase IV inhibitors as new therapeutic agents for the treatment of Type 2 diabetes , 2003 .

[6]  G. Scapin,et al.  (2R)-4-oxo-4-[3-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]-1-(2,4,5-trifluorophenyl)butan-2-amine: a potent, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. , 2005, Journal of medicinal chemistry.

[7]  L. L. Nielsen.  Incretin mimetics and DPP-IV inhibitors for the treatment of type 2 diabetes. , 2005, Drug discovery today.

[8]  R. Mentlein.  Therapeutic assessment of glucagon-like peptide-1 agonists compared with dipeptidyl peptidase IV inhibitors as potential antidiabetic drugs , 2005, Expert opinion on investigational drugs.

[9]  D. D’Alessio,et al.  Gut peptides in the treatment of diabetes mellitus , 2004, Expert opinion on investigational drugs.

[10]  Joseph L Duffy,et al.  4-aminophenylalanine and 4-aminocyclohexylalanine derivatives as potent, selective, and orally bioavailable inhibitors of dipeptidyl peptidase IV. , 2007, Bioorganic & medicinal chemistry letters.

[11]  G. Scapin,et al.  (2S,3S)-3-Amino-4-(3,3-difluoropyrrolidin-1-yl)-N,N-dimethyl-4-oxo-2-(4-[1,2,4]triazolo[1,5-a]-pyridin-6-ylphenyl)butanamide: a selective alpha-amino amide dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. , 2006, Journal of medicinal chemistry.

[12]  J. Holst.  Glucagon-like peptide-1: physiology and therapeutic potential , 2005 .

[13]  L. B. Knudsen.  Glucagon-like peptide-1: the basis of a new class of treatment for type 2 diabetes. , 2004, Journal of medicinal chemistry.

[14]  Ping Chen,et al.  Fluoropyrrolidine amides as dipeptidyl peptidase IV inhibitors. , 2004, Bioorganic & medicinal chemistry letters.

[15]  Joseph L Duffy,et al.  Discovery of potent and selective orally bioavailable beta-substituted phenylalanine derived dipeptidyl peptidase IV inhibitors. , 2005, Bioorganic & medicinal chemistry letters.

[16]  C. Craik,et al.  Catalytic properties and inhibition of proline-specific dipeptidyl peptidases II, IV and VII. , 2003, The Biochemical journal.